The abstract is read at the publisher; the summary is JClub's.
Retifanlimab plus carboplatin-paclitaxel improved overall survival in adult, systemic treatment-naïve advanced/metastatic squamous cell carcinoma of the anal canal, with median OS 32.8 vs 22.2 months.
- Why it matters: Final overall survival data were needed to confirm whether the previously observed progression-free survival advantage translated into clinically meaningful longer survival.
- What they did: In POD1UM-303/InterAACT-2, a phase III randomized double-blind trial with optional crossover, 308 patients were analyzed for OS as a key secondary endpoint.
- The result: Updated efficacy analysis showed OS benefit with HR 0.75 (95% CI 0.55–1.01) and P = 0.0305, with consistent subgroup effects and no new safety signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.